MAP2K7 and melanoma: Overall these data support the involvement of SEMA6A in fibroblasts-induced protection of melanoma cells from the anti-tumor activity of dual BRAF/MEK inhibition and indicate that SEMA6A might be a good candidate predictor of short-term benefit from dual BRAF/MEK blockade.